Meeting
2023 ASCO Annual Meeting
A pilot study of the neoadjuvant use of vemurafenib plus cobimetinib in patients with BRAF-mutant melanoma with palpable lymph node metastases: Survival results.
Authors
Teresa M. Petrella
Sunnybrook Hospital, Toronto, ON, Canada
Teresa M. Petrella , Catalin Liviu Dragos Mihalcioiu , Carolyn Nessim , Alan Spatz , Ian Watson , Frances Catriona Wright
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Melanoma/Skin Cancers
Track
Melanoma/Skin Cancers
Sub Track
Local-Regional Disease
Clinical Trial Registration Number
NCT02036086
Citation
J Clin Oncol 41, 2023 (suppl 16; abstr 9579)
DOI
10.1200/JCO.2023.41.16_suppl.9579
Abstract #
9579
Poster Bd #
342
Abstract Disclosures
Similar Posters
Poster
2017 ASCO Annual Meeting
Patterns of histologic response to neoadjuvant targeted therapy in patients with BRAF mutant melanoma.
First Author: Zeynep Eroglu
Poster
2015 ASCO Annual Meeting
Phase 2 study of cobimetinib in combination with vemurafenib in active melanoma brain metastases (coBRIM-B).
First Author: Melissa K. Yee
Poster
2012 ASCO Annual Meeting
Neoadjuvant epirubicin, gemcitabine, and docetaxel for primary breast cancer: Survival and prognostic factors in two consecutive neoadjuvant phase I/II trials.
First Author: Frederik Marme
Poster
2023 ASCO Annual Meeting
Expanded cohort and extended follow-up of neoadjuvant plus adjuvant (neo + adj) dabrafenib (D) and trametinib (T) in patients (pts) with surgically resectable stage (stg) III/IV melanoma.
First Author: Tarin Hennegan